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Candida species: Species distribution and antifungal 
susceptibility patterns
Tracy Arendse, Heidi Orth
To the Editor: Candida species cause serious infections in the 
immunocompromised and critically ill host. Studies have 
reported an emergence of non-albicans Candida (NAC) spp., 
particularly C. tropicalis, C. glabrata, C. krusei and C. parapsilosis.1 
The widespread use of fluconazole might have contributed 
to this increase in less-susceptible and intrinsically triazole-
resistant Candida species.2 While C. albicans remains the most 
common Candida species isolated at Tygerberg Hospital, 
especially in ICU patients, C. tropicalis and C. parapsilosis have 
emerged as predominant causes of candidaemia in children 
with haematological malignancies, and important pathogens 
in HIV-infected children. Fluconazole was active against all of 
our isolates and therefore continues to be the agent of choice 
for treating candidaemia. Because of changing trends, it is 
necessary to continuously or periodically monitor Candida 
species isolated in any specific setting, as well as antifungal 
activity, but this is not routinely done at many South African 
laboratories.
Methods
We investigated the distribution and antifungal susceptibility 
of Candida species isolated from various clinical specimens 
and antifungal susceptibility patterns of bloodstream isolates 
at Tygerberg Hospital. All consecutive non-duplicate Candida 
species isolated from March to September 2005 were identified 
using the germ tube test and a commercial identification kit 
(Auxacolor 2, Bio-Rad, France). Susceptibility to amphotericin 
B and fluconazole was determined for all blood isolates (E-test 
method, AB BIODISK, Sweden). Results were read after 48 
hours’ incubation and interpreted according to NCCLS M27-
A2, 2002. Quality control was performed using Candida albicans 
ATCC 90028 and Candida tropicalis ATCC 750. Patient data 
analysis included age, sex, specimen type, diagnosis and ward.
Results
Of a total of 119 Candida isolates, 6 were excluded from the 
analyses as no patient details could be retrieved.
Seventy-five per cent of isolates were recovered from adults 
and 25% from children. C. albicans constituted 72%, and NAC 
28%, of all Candida isolates from adult patients. In children,  
C. albicans accounted for 67%, and NAC for 33%, of isolates. 
The adult surgical intensive care unit (ICU) had the highest 
number of C. albicans isolates (15.2%). Other wards with a 
high number of C. albicans isolates included the labour ward 
and obstetric antenatal clinic (predominantly from urine 
specimens), the paediatric ICU, and the paediatric infectious 
diseases ward (predominantly HIV-infected patients). The 
paediatric infectious disease and oncology wards had the 
highest figure for NAC: 11.8% and 8.8% respectively.
C. albicans was the most common species isolated when 
comparing the isolation of C. albicans with NAC from urine 
(29% v. 17%), blood (16% v. 7%) and pus (8% v. 1%). All 
bloodstream isolates, including 17 C. albicans, 4 C. parapsilosis, 
3 C. tropicalis and 1 C. lucitaniae, tested susceptible to both 
fluconazole and amphotericin B.
Discussion
C. albicans (69%) is the most commonly isolated Candida 
species at Tygerberg Hospital, followed by C. glabrata (10%); C. 
parapsilosis (10%); C. tropicalis (4%); C. lusitaniae (2%); C. krusei 
(2%); and C. lipolytica, C. guilliermondii, C. famata (all 1%), which 
is consistent with international published data.3
Septicaemia was the most common diagnosis on the 
laboratory request forms. Positive blood culture isolates were 
mostly isolated from paediatric patients with malignancies 
where NAC predominated, which is consistent with studies 
citing that NAC occurs more frequently in leukaemia 
patients.4 Candida species were also commonly isolated from 
urine. Urinary tract infections are usually associated with 
indwelling urinary catheters, particularly in patients on broad-
spectrum antibiotics, although positive cultures may also 
represent contamination of urine specimens with vaginal flora, 
particularly in cases of vaginal thrush.
A high number of C. albicans were isolated from the surgical 
ICU. In contrast with trends among immunocompromised 
patients, C. albicans remains the predominant strain among 
ICU patients.5 Risk factors for candidaemia include exposure to 
broad-spectrum antibiotics, invasive procedures and prolonged 
ICU stay.
All blood culture isolates tested susceptible to fluconazole, 
which is important since it has advantages over amphotericin 
B, including high oral bioavailability and low incidence of 
side-effects. Amphotericin B-susceptible results for C. lusitaniae 
should be interpreted with caution as this species has a higher 
propensity than other Candida species for developing resistance 
to amphotericin B.6
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Pyruvate kinase deficiency in a South African kindred 
caused by a 1529A mutation in the PK-LR gene 
Pierre M Durand, Theresa L Coetzer
To the Editor: There is currently no investigation for pyruvate 
kinase (PK) deficiency in South Africa and nothing is known 
about local mutations. We describe the implementation of 
a PK assay and document the first mutation underlying PK 
deficiency in a South African patient who presented with a 
haemolytic episode following ARV (antiretroviral) prophylaxis.
PK deficiency is the most common inherited disorder of 
glycolysis in humans.1 The enzyme catalyses the conversion 
of phosphoenolpyruvate (PEP) to pyruvate, producing 
adenosine triphosphate (ATP) from adenosine diphosphate 
(ADP) in the process. A PK deficiency therefore results in 
decreased intra-erythrocytic ATP, which cannot be compensated 
for by oxidative phosphorylation since erythrocytes lack 
mitochondria. This leads to membrane damage, haemolysis 
and premature destruction in the spleen.
Epidemiological studies indicated that the PK heterozygote 
allele frequency ranges from 1% to 5% in Caucasian 
populations, and one small study suggested the frequency 
might be twice as high in African-Americans.2 Areas of 
south-east Asia may have a significantly higher prevalence,2,3 
although there have been no large-scale studies conducted in 
this region. The reason for the relatively high frequency of the 
abnormal PK allele has been debated. The majority of inherited 
erythrocyte disorders have been selected by their relative 
resistance to malaria,4 and we have recently demonstrated that 
PK deficiency protects against malaria in humans (manuscript 
accepted for publication in Haematologica, May 2008), which 
provides a possible explanation.
The prevalence of the disease in South Africa is unknown, 
and few individual cases have been reported (personal 
communication, Dr N Alli, Chris Hani Baragwanath Hospital). 
There is currently no available assay for PK deficiency in South 
Africa, and nothing is known about the underlying mutations 
in the PK-LR gene in South Africans and Africans in general. 
More than 180 mutations cause the disease,3 and it would be 
interesting to establish the mutation spectrum in southern 
Africans.
We report the implementation of an assay for PK activity. A 
patient with suspected PK deficiency was confirmed to have 
the disease, and the underlying mutation was identified.
Methods
PK assay implementation
The PK assay, based on Beutler’s method5 with a few minor 
modifications, was implemented in the Red Cell Membrane 
Unit, Department of Molecular Medicine and Haematology 
at the University of the Witwatersrand National Health 
Laboratory Service (NHLS) in Johannesburg. Qualitative 
(screening) and quantitative (confirmatory) assays were 
implemented, and the screening assay may be added to the 
routine tests offered by the NHLS. Guidelines for physicians 
are available from the authors.
The screening and quantitative assays use the same test 
principle: Plasma and leucocytes are removed from whole 
blood and the packed erythrocytes resuspended in 0.9% 
saline. A 1:20 haemolysate is made of the red cells and used 
to determine PK enzyme activity by the conversion of PEP to 
pyruvate. This reaction is coupled to a second reaction, which 
uses lactate dehydrogenase to convert pyruvate to lactate with 
nicotinamide adenine dinucleotide (reduced form) (NADH) 
as a co-factor. The oxidation of NADH is determined by a loss 
of fluorescence (screening assay) or spectrophotometrically at 
340 nm (quantitative assay), and is used as a measure of PK 
activity.
Ethics clearance was obtained from the Human Research 
Ethics Committee (Medical), of the University of the 
Department of Molecular Medicine and Haematology, University of the Witwa-
tersrand and National Health Laboratory Service (NHLS), Johannesburg
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